A citation-based method for searching scientific literature

Gregory D Jones, Raul Caso, Kay See Tan, Brooke Mastrogiacomo, Francisco Sanchez-Vega, Yuan Liu, James G Connolly, Yonina R Murciano-Goroff, Matthew J Bott, Prasad S Adusumilli, Daniela Molena, Gaetano Rocco, Valerie W Rusch, Smita Sihag, Sandra Misale, Rona Yaeger, Alexander Drilon, Kathryn C Arbour, Gregory J Riely, Neal Rosen, Piro Lito, Haiying Zhang, David C Lyden, Charles M Rudin, David R Jones, Bob T Li, James M Isbell. Clin Cancer Res 2021
Times Cited: 2







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, Raghunadharao Digumarti, Mauro Zukin,[...]. J Clin Oncol 2008
50

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Weiyi Peng, Jie Qing Chen, Chengwen Liu, Shruti Malu, Caitlin Creasy, Michael T Tetzlaff, Chunyu Xu, Jodi A McKenzie, Chunlei Zhang, Xiaoxuan Liang,[...]. Cancer Discov 2016
705
50


Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
T Mok, D R Camidge, S M Gadgeel, R Rosell, R Dziadziuszko, D-W Kim, M Pérol, S-H I Ou, J S Ahn, A T Shaw,[...]. Ann Oncol 2020
56
50

Revisiting IL-2: Biology and therapeutic prospects.
Abul K Abbas, Eleonora Trotta, Dimitre R Simeonov, Alexander Marson, Jeffrey A Bluestone. Sci Immunol 2018
137
50


The BATTLE trial: personalizing therapy for lung cancer.
Edward S Kim, Roy S Herbst, Ignacio I Wistuba, J Jack Lee, George R Blumenschein, Anne Tsao, David J Stewart, Marshall E Hicks, Jeremy Erasmus, Sanjay Gupta,[...]. Cancer Discov 2011
563
50

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
50

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
Luis Paz-Ares, David Vicente, Ali Tafreshi, Andrew Robinson, Hector Soto Parra, Julien Mazières, Barbara Hermes, Irfan Cicin, Balazs Medgyasszay, Jerónimo Rodríguez-Cid,[...]. J Thorac Oncol 2020
54
50

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
50

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2018
50

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
Megan Cully, Han You, Arnold J Levine, Tak W Mak. Nat Rev Cancer 2006
918
50

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
V Gopalakrishnan, C N Spencer, L Nezi, A Reuben, M C Andrews, T V Karpinets, P A Prieto, D Vicente, K Hoffman, S C Wei,[...]. Science 2018
50


Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, Kellie N Smith, Valsamo Anagnostou, Tricia R Cottrell, Matthew D Hellmann, Marianna Zahurak, Stephen C Yang, David R Jones, Stephen Broderick,[...]. N Engl J Med 2018
685
50


Sensitive tumour detection and classification using plasma cell-free DNA methylomes.
Shu Yi Shen, Rajat Singhania, Gordon Fehringer, Ankur Chakravarthy, Michael H A Roehrl, Dianne Chadwick, Philip C Zuzarte, Ayelet Borgida, Ting Ting Wang, Tiantian Li,[...]. Nature 2018
244
50

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Catherine A Shu, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Claud M Grigg, Aliyah Pabani, Robert F Garofano, Mark B Stoopler, Simon K Cheng, Abby White,[...]. Lancet Oncol 2020
100
50

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Julian R Molina, Ping Yang, Stephen D Cassivi, Steven E Schild, Alex A Adjei. Mayo Clin Proc 2008
50

A view on drug resistance in cancer.
Neil Vasan, José Baselga, David M Hyman. Nature 2019
313
50

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P M Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, Maria P Roberti,[...]. Science 2018
50

Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting.
Antonella Sistigu, Francesca Di Modugno, Gwenola Manic, Paola Nisticò. Cytokine Growth Factor Rev 2017
33
50

Thinking Differently about Cancer Treatment Regimens.
Jeff Settleman, João M Fernandes Neto, René Bernards. Cancer Discov 2021
3
50

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
528
50


The Eighth Edition Lung Cancer Stage Classification.
Frank C Detterbeck, Daniel J Boffa, Anthony W Kim, Lynn T Tanoue. Chest 2017
471
50

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
346
50

Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.
William Pao, Chia-Huey Ooi, Fabian Birzele, Astrid Ruefli-Brasse, Michael A Cannarile, Bernhard Reis, Sebastian H Scharf, David A Schubert, Klas Hatje, Nadege Pelletier,[...]. Cancer Discov 2018
34
50

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
Roy S Herbst, David R Gandara, Fred R Hirsch, Mary W Redman, Michael LeBlanc, Philip C Mack, Lawrence H Schwartz, Everett Vokes, Suresh S Ramalingam, Jeffrey D Bradley,[...]. Clin Cancer Res 2015
152
50

Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic.
Emily N Chin, Chenguang Yu, Vincent F Vartabedian, Ying Jia, Manoj Kumar, Ana M Gamo, William Vernier, Sabrina H Ali, Mildred Kissai, Daniel C Lazar,[...]. Science 2020
47
50

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Nadeem Riaz, Jonathan J Havel, Vladimir Makarov, Alexis Desrichard, Walter J Urba, Jennifer S Sims, F Stephen Hodi, Salvador Martín-Algarra, Rajarsi Mandal, William H Sharfman,[...]. Cell 2017
634
50

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Karthik Dhatchinamoorthy, Jeff D Colbert, Kenneth L Rock. Front Immunol 2021
16
50

The acute clinical features of retrograde menstruation.
L L Reti, G D Byrne, R A Davoren. Aust N Z J Obstet Gynaecol 1983
17
50

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Khyati N Shah, Roma Bhatt, Julia Rotow, Julia Rohrberg, Victor Olivas, Victoria E Wang, Golzar Hemmati, Maria M Martins, Ashley Maynard, Jonathan Kuhn,[...]. Nat Med 2019
93
50

The Future of Clinical Trial Design in Oncology.
Anna Spreafico, Aaron R Hansen, Albiruni R Abdul Razak, Philippe L Bedard, Lillian L Siu. Cancer Discov 2021
2
50

CTLA-4 can function as a negative regulator of T cell activation.
T L Walunas, D J Lenschow, C Y Bakker, P S Linsley, G J Freeman, J M Green, C B Thompson, J A Bluestone. Immunity 1994
50

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Corey J Langer, Mary W Redman, James L Wade, Charu Aggarwal, Jeffrey D Bradley, Jeffrey Crawford, Philip J Stella, Mark H Knapp, Jieling Miao, Katherine Minichiello,[...]. J Thorac Oncol 2019
26
50

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J Johnston, Laetitia Comps-Agrar, Jason Hackney, Xin Yu, Mahrukh Huseni, Yagai Yang, Summer Park, Vincent Javinal, Henry Chiu, Bryan Irving,[...]. Cancer Cell 2014
472
50

Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber. Science 2015
50

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
50

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Moshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, John P Ray, Carl G de Boer, Russell W Jenkins, David J Lieb, Jonathan H Chen, Dennie T Frederick, Michal Barzily-Rokni,[...]. Cell 2018
448
50

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn,[...]. Science 2018
655
50


Immune tolerance in liver disease.
Ian N Crispe. Hepatology 2014
132
50


First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, Juliana Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Oscar Juan-Vidal,[...]. Lancet Oncol 2021
82
50

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
239
50

Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.
Marco B Schaaf, Abhishek D Garg, Patrizia Agostinis. Cell Death Dis 2018
185
50

Epithelial-mesenchymal transitions in development and disease.
Jean Paul Thiery, Hervé Acloque, Ruby Y J Huang, M Angela Nieto. Cell 2009
50

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim,[...]. J Clin Oncol 2020
48
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.